Joseph Jurcic, MD
Hematology · New York, NYNPI 1295838076
Payments from drug & device makers
Across 244 payments — averaging $7020.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$553K
- Astellas Pharma Global Development$256K
- AbbVie$170K
- Bristol Myers Squibb$134K
- Genentech, Inc.$125K
- Gilead$95K
- plus $380K from 21 others
Across 13 payments — averaging $476.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$4K
- Astellas Pharma Global Development$2K
- Pfizer$330
- AbbVie$57
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 66 | $552,828 |
| Astellas Pharma Global Development | 30 | $256,226 |
| AbbVie | 27 | $169,524 |
| Bristol Myers Squibb | 13 | $133,700 |
| Genentech, Inc. | 14 | $125,178 |
| Gilead | 4 | $95,220 |
| Sumitomo Pharma America, Inc. | 8 | $85,164 |
| PTC Therapeutics, Inc. | 7 | $61,353 |
| Celularity Inc. | 2 | $53,114 |
| Pfizer | 5 | $48,669 |
| Sanofi US Services Inc. | 9 | $43,562 |
| Seagen Inc. | 1 | $39,079 |
| E.r. Squibb & Sons, L.L.C. | 2 | $17,163 |
| Novo Nordisk | 1 | $9,834 |
| GSK | 1 | $6,075 |
| Incyte Corporation | 4 | $4,184 |
| Geron Corporation | 8 | $3,619 |
| Daiichi Sankyo Inc. | 13 | $3,579 |
| Jazz Pharmaceuticals Inc. | 1 | $3,200 |
| Novartis | 17 | $1,193 |
| AstraZeneca | 4 | $301 |
| Sanofi | 1 | $119 |
| Genentech USA, Inc. | 1 | $117 |
| CTI Biopharma Corp. | 1 | $40 |
| Beigene USA, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
How this compares
$1,713,123 in reported general payments places this provider in the 90th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in New York
- Michael MauroNew York$34.9M
- Adam KittaiNew York$8.2M
- Barry CollerNew York$7.9M
- Ran ReshefNew York$5.4M
- Divaya BhutaniNew York$4.8M
- Richard FurmanNew York$3.1M
- Marissa RybsteinNew York$1.6M
- Allyson OceanNew York$1.5M
- Mark HeaneyNew York$1.3M
- Jeffrey ZwickerNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.